Navigation Links
Evidence found for genes that affect risk of developing Alzheimer's disease
Date:1/17/2008

JACKSONVILLE, Fla. Through one of the largest studies yet of Alzheimers disease (AD) patients and their brothers, sisters, and children, researchers at Mayo Clinic Jacksonville have found strong evidence that genes other than the well-known susceptibility risk factor APOE4 influence who is at risk for developing the neurodegenerative disease later in life.

Studying 25 multigenerational families of individuals diagnosed with late onset Alzheimers disease (LOAD), the most common form of the disorder, as well as hundreds of other participants, the research team found that blood levels of amyloid beta (A) proteins associated with AD were significantly elevated compared to protein found in non-blood relatives, such as spouses.

These first-degree relatives were cognitively normal and age 65 or less many of them too young for symptoms of LOAD to show up.

These results indicate that genetic factors of substantial magnitude lead to significant elevations of A in the blood of asymptomatic, young individuals from extended LOAD families, says the studys lead investigator, Nilufer Ertekin-Taner, M.D., Ph.D. This fits with our hypothesis that A levels rise years before development of the disorder.

The results, which first appeared online in October of last year, will be published in the Feb. 19 issue of Neurology.

The researchers have already identified three candidate genes on chromosome 10 that is associated with LOAD, and at least one of them, the gene that produces insulin degrading enzyme (IDE), is now regarded as a prime candidate for contributing to the disease. IDE degrades both insulin and amyloid protein, and scientists hypothesize that when there is too much insulin in the brain such as due to diabetes or lower expression levels of IDE, this may lead to toxic accumulation of A.

We believe that 60 percent of the risk of developing the most common form of Alzheimers disease is genetic, and a good part of that is APOE4. But other genes are certainly contributing, and they could provide a platform for diagnosis and therapy in the future, says the studys senior author, Neill Graff-Radford, M.B.B.Ch., FRCP.

Dr. Ertekin-Taner estimates that the impact of these three genes could be as large as APOE4, which is a variant of the APOE gene that has been linked to LOAD. Between 30 percent and 70 percent of AD can be attributable to APOE, and we estimate this locus of three genes on chromosome 10 could be as important, she says. The effect of the chromosome 10 locus could be due to multiple genes, with each gene having a smaller effect size than that of APOE.

This study represents a decade of work by the Mayo researchers, who have been instrumental in discovering that one form of A known as A42 is much more toxic than the other common form of A, which is A40. They have also demonstrated that as AD progresses, A42 levels that have been rising for years begin to decline, presumably because more and more of the protein is being deposited within the brain.

Now, all known forms of early onset AD caused by genetic mutations are associated with an elevation of A42, and because there are such strong genetic determinants of these rarer forms of AD, the Mayo researchers speculated that the common late onset form may also be caused, in part, by genes that raise A levels.

In 2000, the team, led by Dr. Ertekin-Taner, published findings in Science magazine that targeted chromosome 10 as the site of some of these genes, whose function was unknown at the time. They had made the discovery by looking at 10 families of LOAD patients, and two other non-Mayo research teams published similar findings. The Neurology study is a continuation, and expansion, of that discovery.

This time, Mayo researchers collected data on 25 extended multigenerational LOAD families. In addition they studied 103 first-degree relatives of AD patients as well as a group of 116 participants in the federally-funded Mayo Clinic Study of Aging, who served as their comparison group. None of the study participants have been diagnosed with AD. They selected younger first-degree relatives and controls (age 20-65) to study so as to minimize the effect of age on A levels, and they also tested participants for their APOE variant. In a series of sub-studies in control groups, the investigators confirmed that blood A levels stayed consistent over a period of weeks, and that both A40 and A42 levels rise significantly in people over age 65 who do not have dementia.

In the young, cognitively normal first-degree relatives of LOAD patients, they found that levels of both A40 and A42 in the blood were significantly elevated, compared to their spouses (which served as the control group). Studying the other group of 103 first-degree relatives of AD patients, the researchers also found significantly higher levels of A42.

Overall, comparing first-degree relatives with non-relatives, they found that for A42, the average level for the first-degree relatives is about 1.21.3 times that of non-relatives, and for A40, it was 1.11.4 times greater. Just like measuring cholesterol in the blood, the absolute magnitude of such an increase does not have to be large in order to be worrisome, Dr. Ertekin-Taner says.

They then determined that this rise in A is not due to the APOE4 gene. On the contrary, the plasma A levels of relatives with the APOE4 gene variant were lower significantly so for A42 than the levels of those who lacked the gene. This means two things, says co-author Steven Younkin, M.D., Ph.D.: that genetic factors other than the ones already known must lead to plasma A elevations in first-degree LOAD relatives, and that there is a strong mechanistic interaction between APOE4 and A leading to increased deposition of A in the brain and hence lower plasma A levels in these subjects.

These findings indicate that there are genetic elevations in A levels in LOAD that cannot be explained by shared family environment, Dr. Younkin says.

The results also suggest that it is conceivable that plasma A, along with other information such as genetic variants, neuroimaging and cognitive test results, may be used in the future to identify individuals at risk for developing AD, before the onset of disease symptoms, Dr. Ertekin-Taner says.


'/>"/>

Contact: Cynthia Nelson
nelson.cynthia1@mayo.edu
904-953-0464
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. More evidence suggests diabetes drug may be dangerous
2. Evidence links anemia drugs with leukemic transformation in patients with primary myelofibrosis
3. Evidence of TB Found in 500,000-Year-Old Fossil
4. Diet and cancer prevention: New evidence for the protective effects of fruits and veggies
5. Wiley-Blackwell and U. of Penn Health Systems Center for Evidence-Based Practice launch InfoPOEMs
6. UC Davis researchers find evidence of mature heart cell potential in embryonic stem cells
7. Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace
8. Scientific evidence of the significant anti-cancer effect of milk thistle
9. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
10. U of M study: Medicare lacks tools, incentives to enforce evidence-based coverage policies
11. Consumers Should Demand Evidence, Not Guesswork, On Meat-Cancer Links
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology: